Loading...
Loading...
LXRX| Name | Value |
|---|---|
| Revenues | 28.9M |
| Cost of Revenue | 0.2M |
| Gross Profit | 28.7M |
| Operating Expense | 24.9M |
| Operating I/L | 3.7M |
| Other Income/Expense | -0.5M |
| Interest Income | 1.8M |
| Pretax | 3.3M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | 3.3M |
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery, development, and commercialization of orally-delivered small molecule drug candidates. Its lead products include Sotagliflozin, which has completed Phase III clinical trials for the treatment of heart failure and type 1 diabetes, and LX9211, currently in Phase II clinical development for neuropathic pain treatment. The company generates revenue through strategic collaboration and license agreements with industry leaders such as Bristol-Myers Squibb Company and Genentech, Inc., leveraging its innovative drug pipeline to address unmet medical needs and drive commercial success.
